← BioTransfer GEO Dataset Finder
GEO series

Investigating the Therapeutic Potential of the Antioxidant Epigallocatechin Gallate in Fetal Alcohol Spectrum Disorders: Cognition and RNASeq

GSE307141 Homo sapiens (human) RNA-seq (gene expression) 16 samples Submitted 2025/12/28 Platform GPL16791
At a glance

RNA-seq (gene expression) · human · 16 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Homo sapiens (human)
Samples
16 samples: 16 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disordersScientific reports · 2026
Summary (written by the submitters)
Prenatal alcohol exposure (PAE) impacts fetal development, leading to Fetal Alcohol Spectrum Disorders (FASD) characterized by cognitive, behavioral, and physical impairments. This study explores Epigallocatechin Gallate (EGCG), a potent antioxidant and modulator of neuronal plasticity, as a therapeutic intervention for FASD improvement.
Read the full summary ↓
In a 12-month pilot study, patients with 40 FASD received 9 mg/kg/day of EGCG, with outcomes assessed through RNA sequencing of blood samples and neurocognitive evaluations (WISC-IV, CBCL 6-18, and NEPSY-II). Reduced levels of oxidative stress were observed after 6 months of daily treatment with EGCG, to maintain the bioavailability of the molecule in the body, with decreased levels of MDA and 8-isoprostane and increased activity of LDH. Significant neurocognitive improvements were shown after one year of treatment in Perceptual Reasoning Index (PRI) and Working Memory Index (WMI) using the WISC-IV test. CBCL test revealed an improvement in aggressive behavior scores after EGCG treatment. NEPSY-II assessment showed improvements in face memory, and delayed face memory. Interestingly, no significant improvements were observed in intelligence quotient, attention, anxiety, or depression, which affect a proportion of individuals diagnosed with FASD. Additionally, EGCG modulates molecular pathways associated with neuroinflammation, oxidative stress, immune response, and neurogenesis. This study highlights EGCG as a potential therapeutic candidate to ameliorate cognitive and behavioral deficits caused by PAE in children affected by FASD, revealing potential pathways and biomarkers that contribute to these improvements. These advancements ultimately aim to enhance the quality of life for FASD patients and their families.
Published in
Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disorders
Ramos-Triguero A, Astals-Vizcaino M, Navarro-Tapia E et al. · Scientific reports 2026 · PMID 41484421 · doi:10.1038/s41598-025-34576-1
This dataset
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE307141_RAW.tar (it can run to tens of gigabytes).

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1314641 and SRA study SRP617419. Searching any of these in the dataset finder brings you back here.

Study design
16 samples, each with a distinct title — no replicated groups

Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.

How we read this: Read from 16 sample titles: 16 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
Datasets on a similar topic

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.